Krónikus gyulladásos demielinizációs polineuropátia (CIDP): vizsgálatok itt: Csehország
8 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 19.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Where
- Brno, Novy Hradec Kralove, Ostrava, Pardubice, Prague 2
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- Sanofi
See details and how to joinNCT06290141 · EU 2023-508338-33-00 - 3. fázisTaking peopleA Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
- Where
- Brno
- Életkor
- 18 év and over
- People
- 218 worldwide
- Run by
- argenx
See details and how to joinNCT06920004 · EU 2024-520097-36-00 - 3. fázisTaking peopleA Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
- Where
- Brno
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- argenx
See details and how to joinNCT07091630 · EU 2025-520805-10-00 - 3. fázisTaking peopleA Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Where
- Hradec Králové
- Életkor
- 18 év and over
- People
- 40 worldwide
- Run by
- Grifols Therapeutics LLC
See details and how to joinNCT07540221 - 2/3. fázisFut, nem toborozEfficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Where
- Novy Hradec Kralove
- Életkor
- 18 év and over
- People
- 201 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05327114 · EU 2023-508425-28-00 - 3. fázisCsak meghívásosLong-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
- Where
- Brno, Prague
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- Sanofi
See details and how to joinNCT06859099 · EU 2024-517032-22-00 - 3. fázisTaking peopleA Phase III study to evaluate how the body processes Xembify in comparison to Gamunex-C and determine the safety and in people with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Where
- Hradec Králové
- Életkor
- 18 év and over
- People
- 20 worldwide
- Run by
- Grifols Therapeutics LLC
See details and how to join2025-522165-30-00 - 3. fázisBefejeződöttA Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Where
- Hradec Králové
- Életkor
- 18 év and over
- People
- 59 worldwide
- Run by
- Takeda
See details and how to joinNCT06747351 · EU 2024-517450-95-00